Cardiol Therapeutics faced a significant setback in market confidence yesterday, resulting in a sharp decline in its stock price.
Cardiol Therapeutics Inc Class A (CRDL.TO) saw its stock drop by 8.97% during yesterday's trading session, closing at CA$2.03. This decline raises questions about the company's current market position and future prospects.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$270.97M
52W high
$3.23
52W low
$1.23
1W change
-8.23%
Beta
0.61
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 284.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+284.6% Upside
Current Price
C$1.56
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
71.8%
Annualized
90-Day Vol
63.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.67
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.37 | C$1.85 – C$3.03 |
| 60 trading days | C$2.51 | C$1.77 – C$3.57 |
| 90 trading days | C$2.67 | C$1.74 – C$4.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Cardiol Therapeutics struggles to maintain momentum in a challenging market environment.
Stock Price Falls to CA$2.03
Cardiol Therapeutics' market cap now stands at approximately CA$270.97 million, reflecting investor concerns following the stock's sharp decline.
Bull case
The company recently hit its Phase III MAVERIC trial enrollment target ahead of schedule. If the trial results are positive, this could indicate strong future performance for Cardiol.
Bear case
Despite these recent milestones, the significant drop in stock price shows a decline in investor confidence. This may stem from market volatility or worries about the company's financial health.
Advertisement
Market Reaction to Recent Developments
Even with the successful enrollment in the Phase III MAVERIC trial, Cardiol Therapeutics' stock fell sharply. Investors might be considering the implications of the company's recent warrant exercise and its ongoing financial strategies, which could be fueling the negative sentiment.
Investor Sentiment and Future Outlook
The substantial drop in Cardiol's stock price reflects broader concerns among investors about the company's ability to turn clinical trial success into financial stability. As the market reacts to these developments, investors should keep a close eye on the upcoming results from the MAVERIC trial and any further financial updates from the company. For more insights, check out our detailed analysis on Cardiol Therapeutics.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
